Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients
DRKS00004981Phase 3Completed
- Sponsor
- European Association of Urology
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised trial of zoledronic acid in prostate cancer (PCa) (2 arms), sponsored by European Association of Urology. Started Jun 2014; status: completed.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on DRKS00004981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004981.